US10231965 — Molecules for administration to ROS1 mutant cancer cells
Method of Use · Assigned to Nerviano Medical Sciences SRL · Expires 2035-02-17 · 9y remaining
What this patent protects
This patent discloses substituted indazole derivatives and their pharmaceutical compositions for use in treating diseases associated with deregulated protein kinase activity, such as cancer.
USPTO Abstract
Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Drugs covered by this patent
- Rozlytrek (entrectinib) · Roche
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2618 |
— | Rozlytrek |
U-2618 |
— | Rozlytrek |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.